Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$1.56 USD
+0.06 (4.00%)
Updated May 28, 2024 04:00 PM ET
After-Market: $1.54 -0.02 (-1.28%) 7:22 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CATX 1.56 +0.06(4.00%)
Will CATX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CATX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CATX
PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
CATX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
Other News for CATX
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Perspective Therapeutics (CATX) and Glaukos (GKOS)
Perspective Therapeutics management to meet with Oppenheimer
Perspective Therapeutics: An Elevated Theranostics Play Flying Under Your Radar
Buy Rating Affirmed for Perspective Therapeutics Amid Promising Competitor Data and Treatment Innovations
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants